KMS Medisurgi Ltd

KMS Medisurgi Ltd has announced that its Board of Directors will convene on September 5, 2026. The meeting agenda includes crucial items such as approving the date, time, and venue for the 28th Annual General Meeting (AGM), along with the Directors' Report and Notice for the AGM. The board will also consider and recommend the financial statements for the fiscal year ended March 31, 2026, and the Management Discussion and Analysis Report. Additionally, they will discuss the closure of the Register of Members and Share Transfer Books, potential final dividend, and the appointment of a scrutinizer for the AGM's voting process.

KMS Medisurgi Ltd has informed the exchange that it is not required to submit the Corporate Governance Report for the quarter ended June 30, 2026. This exemption is due to the company being listed on the BSE SME Platform, and meeting the criteria under Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Specifically, the company's paid-up equity share capital and net worth fall below the thresholds that mandate compliance with certain corporate governance provisions.

KMS Medisurgi Ltd has submitted standalone audited financial results for the year ended March 31, 2026, as per SEBI regulations. The board approved the results along with the Independent Auditors' Report, which includes a qualified opinion due to concerns regarding Post-Employment Benefits accounting and stock record reconciliation. The auditor's report mentions a qualified opinion due to deviations from AS-15 and pending stock reconciliation of ₹253.80 Lacs.

KMS Medisurgi Ltd has submitted its standalone audited financial results for the year ended March 31, 2026, as per SEBI regulations. The board approved the results along with the Independent Auditors Report, which includes a qualified opinion due to concerns regarding Post-Employment Benefits and stock records. The auditor's qualified opinion highlights a departure from AS-15 on Employee Benefits due to the lack of an actuarial report for Post-Employment Benefits and other long-term employee benefits. Additionally, the company is in the process of reconciling stock records, with a closing stock valued at ₹253.80 Lacs.

KMS Medisurgi Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the standalone audited financial results for the year ended March 31, 2026. The meeting will take place at the company's registered office in Mumbai. The trading window for dealing in the company's equity shares has been closed since April 1, 2026, and will remain closed until 48 hours after the financial results are communicated to the Stock Exchange.

A meeting of the Board of Directors of KMS Medisurgi Limited will be held on Saturday, May 30, 2026, at 02.00 pm at the registered office of the company. The board will consider and approve the standalone audited financial results for the year ended March 31, 2026. The trading window has been closed from April 01, 2026 and will remain closed until 48 hours after the financial results are communicated to the stock exchange.

Mr. Pratik Pravin Tarpara has ceased to be an Independent Director of KMS Medisurgi Ltd effective September 30, 2025, upon completion of his tenure. This follows Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company acknowledged his contributions during his term. Details regarding the cessation are provided in Annexure A as per SEBI guidelines.

KMS Medisurgi Ltd announced that Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates an Annual Secretarial Compliance Report, is not applicable to the company. This exemption is granted under Regulation 15(2) of SEBI (LODR) Regulations, 2015, because the company is listed on the BSE SME Platform. Consequently, KMS Medisurgi is not required to submit the Annual Secretarial Compliance Report.

KMS Medisurgi Ltd has announced its exemption from submitting the Corporate Governance Report as per Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This non-applicability stems from the company's listing on the BSE SME Platform, which qualifies it under Regulation 15(2) of the same regulations. Consequently, KMS Medisurgi is not required to disclose the Report on Corporate Governance for the year ended March 31, 2026.

KMS Medisurgi Ltd, with scrip code 540468, has announced the closure of its trading window. This closure will be in effect from 1st April 2026 until 48 hours after the announcement of the Audited Financial Results for the half year and year ended 31st March 2026. This move is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.